Non-secretory multiple myeloma (NSMM) is a rare variant of the classic form of multiple myeloma (MM). In NSMM, no monoclonal gammopathy can be detected in serum or urine by conventional techniques, making the diagnosis more difficult. We describe a 71-year-old man who had been diagnosed and treated for granulocytic sarcoma one year prior to his recent problems of progressive low-back pain of two months duration. Skeletal X-rays showed diffuse osteolytic lesions with multiple pathological fractures but there was no monoclonal gammopathy in the serum or urine. The biopsy of the lytic lesion on the upper part of the femur showed infiltration by abnormal plasma cells. A diagnosis of NSMM was made and he was treated with chemotherapy. The early diagnostic difficulty and the challenges faced regarding the case are discussed.

Download full-text PDF

Source

Publication Analysis

Top Keywords

multiple myeloma
12
non-secretory multiple
8
myeloma nsmm
8
monoclonal gammopathy
8
serum urine
8
myeloma diagnostic
4
diagnostic challenges
4
challenges non-secretory
4
nsmm rare
4
rare variant
4

Similar Publications

The definition of high-risk (HR) multiple myeloma (MM) is still a matter of debate. We prospectively evaluated the HR detection using FISH in combination with SKY92 gene expression profiling in 258 MM patients (newly diagnosed [ND] MM:  = 109; relapsed/refractory [RR] MM:  = 149). HR SKY92 was significantly enriched in RRMM (57/121, 47.

View Article and Find Full Text PDF

Plasmacytomas are rare monoclonal neoplastic plasma cell proliferations in soft tissue or bone, with clival plasmacytomas being extremely rare and occasionally presenting with light chain deposition disease (LCDD). While imaging findings for clival plasmacytomas have shown variable T2 signal characteristics, complete T2 signal loss has not been previously reported. We present a case of a 61-year-old female found to have a 1.

View Article and Find Full Text PDF

Despite advancements in multiple myeloma treatment, prognostic variability persists. We investigated the impact of income and education on treatment and survival in a country with publicly funded healthcare. We analysed data from the Swedish Myeloma Registry (2008-2021) linked to national registers.

View Article and Find Full Text PDF

The efficacy and safety of total marrow irradiation (TMI) plus a reduced dose of melphalan as autologous stem cell transplantation (ASCT) preconditioning for multiple myeloma (MM) patients were evaluated. The 11 patients with MM had a median age of 57 (range: 46-75) years; six of them were at standard risk and five of them were at high risk based on the Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART) standard risk factors. Before ASCT, three patients achieved stringent complete response (sCR), two patients achieved complete remission (CR), and the rest of the patients had either partial response (PR) or progressive disease.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!